/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

Z

Zefei Jiang

Qingdao University(CN)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

376

Papers

15.5K

Citations

46

h-index

115

i10-index

Zefei Jiang is an academic researcher from Qingdao University. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies. The author has an h-index of 46, co-authored 320 publications.

ORCID: 0000-0002-4295-0173

Research Topics

HER2/EGFR in Cancer Research Advanced Breast Cancer Therapies Breast Cancer Treatment Studies Cancer Treatment and Pharmacology Cancer Genomics and Diagnostics

Papers by this author

works

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

2013 · Annals of Oncology · 3,628 citations

https://doi.org/10.1093/annonc/mdt303

Aron Goldhirsch Eric P. Winer Alan S. Coates Richard D. Gelber

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

2015 · Annals of Oncology · 1,820 citations

https://doi.org/10.1093/annonc/mdv221

Alan S. Coates Eric P. Winer Aron Goldhirsch Richard D. Gelber

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

2017 · The Lancet Oncology · 532 citations

https://doi.org/10.1016/s1470-2045(17)30376-5

José Baselga Seock‐Ah Im Hiroji Iwata Javier Cortés

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

2010 · Journal of Clinical Oncology · 523 citations

https://doi.org/10.1200/jco.2009.25.8707

Harold J. Burstein Yan Sun Luc Dirix Zefei Jiang

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

2021 · Annals of Oncology · 370 citations

https://doi.org/10.1016/j.annonc.2021.09.015

Nadia Harbeck Priya Rastogi Miguel Martín Sara M. Tolaney

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

2019 · Journal of Clinical Oncology · 338 citations

https://doi.org/10.1200/jco.19.00108

Fei Ma Quchang Ouyang Wěi Li Zefei Jiang

Research topics

topics

HER2/EGFR in Cancer Research

Advanced Breast Cancer Therapies

Breast Cancer Treatment Studies

Cancer Treatment and Pharmacology

Cancer Genomics and Diagnostics

Chat about Author

Papers

Chat

Click to start Chat